Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

REGN3500

- PMLiVE

Sanofi and McLaren Racing come together to maximise performance and operational excellence

The partnership will complement Sanofi’s R&D pipeline, which has 25 new launches planned over the next five years

- PMLiVE

Sanofi’s Rezurock results show positive patient outcomes

Pooled analysis of chronic graft-versus-host disease treatment demonstrates organ clinical responses correlated with meaningful changes

regeneron headquarters

Regeneron set to acquire Checkmate for approximately $250m

The deal is expected to be finalised in mid-2022

- PMLiVE

Sanofi begins construction on the first of two Evolutive Vaccine Facilities in Singapore

The two sites aim to improve pandemic preparedness and will have an estimated cost of $1.3bn over the next five years

- PMLiVE

Sanofi’s asthma treatment approved by European Commission

Dupixent is suitable for 6- to 11-year-old children who have severe asthma and type 2 inflammation

- PMLiVE

Sanofi launches Diversity, Equity & Inclusion Board

The Board is the first of its kind in the pharma industry to have outside advisors

- PMLiVE

Sanofi and IGM Biosciences agree on deal potentially worth over $6bn

The deal focuses on research into oncology, immunology and inflammation targets

- PMLiVE

Sanofi and Regeneron share positive trial results for patients with uncontrolled prurigo nodularis

The results were announced at the American Academy of Dermatology 2022 Annual Meeting

- PMLiVE

Sanofi reveals $330m collaboration with Blackstone Life Sciences

The partnership will focus on innovative treatment for multiple myeloma

- PMLiVE

Sanofi experiences setback in phase 2 breast cancer trial

The AMEERA-3 trial tested women aged 18 and over with hormone receptor-positive, HER2-negative advanced breast cancer

- PMLiVE

Sanofi and Regeneron announce positive phase 3 trial results for Dupixent

The trial involved patients with eosinophilic oesophagitis, an inflammatory disease that damages the oesophagus and makes eating and drinking painful

- PMLiVE

FDA accepts Priority Review for Dupixent in children with moderate-to-severe atopic dermatitis

If approved, Dupixent would be the first biologic treatment available in the US for children aged six months to five years with the skin condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links